U.S. markets close in 5 hours 56 minutes

Rubius Therapeutics, Inc. (RUBY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.73-0.65 (-6.22%)
As of 10:03AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close10.38
Open10.35
Bid9.58 x 1300
Ask9.67 x 1000
Day's Range9.50 - 10.53
52 Week Range3.35 - 15.99
Volume327,746
Avg. Volume1,457,421
Market Cap790.226M
Beta (5Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)-2.08
Earnings DateFeb 23, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.90
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
    GlobeNewswire

    Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

    CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 11:20 a.m. EST. A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook. Contacts: InvestorsElhan Webb, CFA, VP Investor Relationselhan.webb@rubiustx.com Media Marissa Hanify, Director, Corporate Communicationsmarissa.hanify@rubiustx.com Dan Budwick, 1AB+1 (973) 271-6085dan@1abmedia.com

  • Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
    GlobeNewswire

    Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results

    CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is using its platform to genetically engineer red blood cells into medicines, called Red Cell Therapeutics™, for the treatment of cancer and autoimmune diseases, today announced plans to report fourth quarter and full year 2020 financial results on Tuesday, February 23, 2021, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics’ manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook. Contacts:Elhan Webb, CFAVice President, Investor Relationselhan.webb@rubiustx.comMedia: Marissa HanifyDirector, Corporate Communicationsmarissa.hanify@rubiustx.com Dan Budwick1AB +1 (973) 271-6085dan@1abmedia.com

  • Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days
    GlobeNewswire

    Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days

    CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the Guggenheim Healthcare Talks | 2021 Oncology Days on February 11, 2021, at 2:30 p.m. EST. A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook. Contacts: InvestorsElhan Webb, CFA, VP Investor Relationselhan.webb@rubiustx.com Media Marissa Hanify, Director, Corporate CommunicationsMarissa.hanify@rubiustx.com Dan Budwick, 1AB+1 (973) 271-6085dan@1abmedia.com